Thioguanine administered as a continuous intravenous infusion to pediatric patients is metabolized to the novel metabolite 8-hydroxy-thioguanine.

Kitchen, B J; Moser, A; Lowe, E; Balis, F M; Widemann, B; Anderson, L; Strong, J; Blaney, S M; Berg, S L; O'Brien, M; Adamson, P C

Kitchen, B J; Moser, A; Lowe, E; Balis, F M; Widemann, B; Anderson, L; Strong, J; Blaney, S M; Berg, S L; O'Brien, M; Adamson, P C.

Affiliation

Kitchen BJ; Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.

J Pharmacol Exp Ther ; 291(2): 870-4, 1999 Nov.

Article in En | MEDLINE | ID: mdl-10525111

Subject(s)

Aldehyde Oxidoreductases/physiology; Antimetabolites, Antineoplastic/metabolism; Thioguanine/analogs & derivatives; Thioguanine/administration & dosage; Thioguanine/metabolism; Aldehyde Oxidase; Antimetabolites, Antineoplastic/administration & dosage; Antimetabolites, Antineoplastic/blood; Child; Chromatography, High Pressure Liquid; Humans; In Vitro Techniques; Infusions, Intravenous; Mass Spectrometry; Thioguanine/blood

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Thioguanine / Aldehyde Oxidoreductases / Antimetabolites, Antineoplastic Limits: Child / Humans Language: En Journal: J Pharmacol Exp Ther Year: 1999 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links